Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) 800 mg administered orally
twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid
Cardiomyopathy (ATTR-CM).
Phase:
Phase 3
Details
Lead Sponsor:
Eidos Therapeutics Eidos Therapeutics, a BridgeBio company